KeyBanc cuts NeuroPace stock price target on lowered estimates
KeyBanc reduced its price target on NeuroPace (NPCE) to $14 from $18, citing lower growth estimates after Q3 2026 revenue fell short. The company expects 5% growth in Q4 2026 and 15% in 2027. NPCE shares are down 22% YTD, trading at $12.02. KeyBanc maintains an Overweight rating, noting potential upside despite near-term challenges.
How this was made
The 30-second read
Why it matters
Guidance cut and revenue miss drive negative sentiment; however, management cites future product growth.
Market read
The downgrade adds to bearish pressure on NPCE, a small‑cap biotech, with limited broader market effect.
What to watch
Potential upside from upcoming RNS product growth and 2027 outlook could offset short‑term weakness.
Background
NPCE develops neurostimulation devices; the company reported Q3 2026 revenue of $23.1M versus $27.1M expected.
Ticker impact
KeyBanc cut NPCE's price target to $14 from $18 after reporting a Q3 revenue miss and lowered guidance.
likely pressure as the market prices in the guidance cut and revenue miss
Analyst downgrade with lower target and weak Q3 results typically trigger sell‑offs in small‑cap stocks.
Market effects
May weigh on other neurostimulation device makers as guidance concerns spread.
Limited to US small‑cap biotech sector.
Low; impact confined to NPCE and its niche sector.
Counterpoint
Some investors may see the lower target as an entry point if they believe clinical catalysts will materialize.
Key entities
- analystKeyBanc
Research firm that lowered the price target.


